Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation. All patients with non-PD after induction therapy who remain surgical candidates will undergo surgical resection 4-12 weeks following induction therapy.

After surgical resection, all patients who remain eligible will be treated with adjuvant Durvalumab every 4 weeks for 6 cycles beginning 4-12 weeks after surgical resection.
Non Small Cell Lung Cancer|Stage III Non-small-cell Lung Cancer
DEVICE: Durvalumab|DRUG: Paclitaxel|DRUG: Carboplatin|RADIATION: Radiation|PROCEDURE: Surgical Resection
Pathologic Complete Response Rate, Pathologic Complete Response Rate is defined as lack of evidence of viable cancer in the surgical specimen at the time of surgery., 3 months
Pathologic N0 Rate, Pathologic N0 rate is defined as a lack of evidence of viable cancer in the removed lymph nodes at the time of surgery., 3 months|Assess Adverse Events (AE), Adverse events, \>= grade 3 and related to treatment will be summarized by frequency and severity according to the NCI Common Terminology Criteria for (NCI CTCAE) v5, AEs had been recorded from time of signed informed consent until 90 days after discontinuation of study drug(s) or until a new anti-cancer treatment starts, whichever occurs first, up to a maximum of 13 months.|Disease Free Survival (DFS), Disease free survival will be defined as the time from surgical resection until the criteria for disease recurrence is met or death as a result of any cause. Disease recurrence is return of the cancer to where it started (local) or in another part of the body (distant)., Time from surgical resection until disease recurrence or death, up to a maximum of 8 months
This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation. All patients with non-PD after induction therapy who remain surgical candidates will undergo surgical resection 4-12 weeks following induction therapy.

After surgical resection, all patients who remain eligible will be treated with adjuvant Durvalumab every 4 weeks for 6 cycles beginning 4-12 weeks after surgical resection.